Radiofrequency Ablation Devices Market Size Worth $7,711.72 Million, Globally, by 2027 at 11.5% CAGR - Exclusive Report by The Insight Partners
16 déc. 2021 07h41 HE
|
The Insight Partners
New York, Dec. 16, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Radiofrequency Ablation Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product...
Bone Tumor Ablation Devices Market size worth $ 344.89 Million, Globally, by 2028 at 8.21% CAGR: Verified Market Research®
15 nov. 2021 11h15 HE
|
Verified Market Research
Jersey City, New Jersey, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Bone Tumor Ablation Devices Market” By End User (Hospitals, Ambulatory Surgical...
Global Interventional Oncology Ablation Market to Surpass US$ 766.6 Million by 2027, Says Coherent Market Insights (CMI)
19 août 2021 08h40 HE
|
CMI
SEATTLE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Global Interventional Oncology Ablation Market to Surpass US$ 766.6 Million by 2027, Says Coherent Market Insights (CMI) According to Coherent Market...
Global Radiofrequency Ablation Devices Market Analysis & Demand Report 2021-2030
21 juin 2021 04h13 HE
|
Research and Markets
Dublin, June 21, 2021 (GLOBE NEWSWIRE) -- The "Radiofrequency Ablation Devices Market Research Report: By Component (Catheter Systems, Generators, Accessories), Application (Oncology, Cardiology,...
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
13 juil. 2020 08h30 HE
|
Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
04 févr. 2020 08h30 HE
|
Celsion CORP
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) --...
Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
23 sept. 2019 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
05 août 2019 09h00 HE
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
Radiofrequency Ablation Devices Market Size Worth Around USD 6.2 billion by 2026: Acumen Research and Consulting
09 avr. 2019 10h00 HE
|
Acumen Research and Consulting
LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- The global Radiofrequency Ablation Devices market is forecasted to grow at a stable CAGR around 11% during the forecast period 2018 to 2026 and reach...